MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.26716

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2016

Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.

Chandrasekhar Jaya, Bansilal Sameer, Baber Usman, Sartori Samantha, Aquino Melissa, Farhan Serdar, Vogel Birgit, Faggioni Michela, Giustino Gennaro, Ariti Cono, Colombo Antonio, Chieffo Alaide, Kini Annapoorna, Saporito Richard, Michael Gibson C, Witzenbichler Bernhard, Cohen David, Moliterno David, Stuckey Thomas, Henry Timothy, Pocock Stuart, Dangas George, Gabriel Steg P, Mehran Roxana

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Proton pump inhibitors (PPI) may decrease the availability of clopidogrel by competitive antagonism, leading to a potential increase in ischemic events.

METHODS

We evaluated patients from the all-comer PARIS registry treated with dual antiplatelet therapy (DAPT) with aspirin and clopidogrel following coronary stenting for outcomes stratified by PPI use. Two-year major adverse cardiovascular events (MACE), composite of cardiac death, myocardial infarction, definite or probable stent thrombosis or target lesion revascularization (TLR), and net adverse cardiac events (NACE), composite of MACE or Bleeding Academic Research consortium (BARC) type 3 or 5 bleeding were assessed. We also explored associations between PPI use and patterns of 2-year DAPT cessation.

RESULTS

The cohort comprised 4635 patients (23% PPI users) with mean age 64.4 ±11.4 years. Two year adjusted risk of MACE (HR: 1.27, 95% CI: 1.04-1.55), NACE (HR: 1.21, 95% CI: 1.01-1.44) and TLR (HR: 1.33, 95% CI: 1.04-1.71) were significantly higher in PPI users vs. non-users, without a difference in bleeding. Although the incidence of 2-year DAPT discontinuation and interruption was similar, DAPT disruption was significantly lower among PPI users vs. non-users (10.0% vs. 14.7%, P <0.0001). Compared to non-PPI users on continued DAPT, disruption was associated with higher MACE in both PPI users (HR: 2.34, 95% CI: 1.38-3.97) and non-users (HR: 1.41, 95% CI: 1.02-1.94) but greater BARC 3,5 bleeding only in non-PPI users (HR: 2.06, 95% CI: 1.21-3.51).

CONCLUSIONS

In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding. PPI use was associated with lower incidence of DAPT disruption without an increase in disruption related bleeding compared to non-PPI users on DAPT. © 2016 Wiley Periodicals, Inc.

Для цитирования: Chandrasekhar Jaya, Bansilal Sameer, Baber Usman, Sartori Samantha, Aquino Melissa, Farhan Serdar, Vogel Birgit, Faggioni Michela, Giustino Gennaro, Ariti Cono, Colombo Antonio, Chieffo Alaide, Kini Annapoorna, Saporito Richard, Michael Gibson C, Witzenbichler Bernhard, Cohen David, Moliterno David, Stuckey Thomas, Henry Timothy, Pocock Stuart, Dangas George, Gabriel Steg P, Mehran Roxana. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2016. DOI: 10.1002/ccd.26716.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.